Cytokinetics, Incorporated awaits a pivotal FDA decision on aficamten for hypertrophic cardiomyopathy. Learn more about CYTK ...
Right now, the HALT Study is underway to provide the substantial evidence of effectiveness necessary for the full FDA approval of Felycin-CA1 (referred to as TRIV202 in HALT) for the management of ...
Extra scrutiny is warranted to identify the underlying causes of chest pain in patients with nonobstructive coronary disease ...
Patients with undiagnosed sleep disordered breathing and hypertrophic cardiomyopathy may have subclinical myocardial injury.
Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficamten. | ...
Zacks Investment Research on MSN
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
Bristol Myers BMY announced that it will discontinue the late-stage Librexia study evaluating the efficacy and safety of ...
System of Care to Advance Care for the Most Commonly Inherited Heart DiseaseSOUTH SAN FRANCISCO, Calif., (GLOBE NEWSWIRE) -- ...
Lexicon Pharmaceuticals targets a turnaround with sotagliflozin, LX9851, pilavapadin, and partnerships offering multiple ...
Chest pain may still be angina even when the main heart arteries look clear. Using cardiac stress MRI (a heart scan that measures blood flow with magnetic resonance imaging), testing uncovered small ...
Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Here, we report the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback